Rituximab in dermatological diseases

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 4, 2009, Pages 495-499

  Troiano, M ^a   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Autoimmune diseases, therapy; Lymphoma, non Hodgkin; Rituximab; Skin diseases

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACTERIAL INFECTION; BRONCHOSPASM; BULLOUS PEMPHIGOID; CHILL; DEEP VEIN THROMBOSIS; DERMATOMYOSITIS; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DYSPNEA; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; HEADACHE; HUMAN; HYPOTENSION; LUNG INSUFFICIENCY; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA; VIRUS INFECTION;

EID: 72249111322     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Bates JS, Engemann AM, Hammond JM. Clinical utility of Rituximab in chronic graft-versus-host-disease. Ann Pharmacother 2009;43:316-21.
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletation of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445
3. Collins-Burow B, Santos ES. Rituximab and its role as maintenance therapy in non-Hodgking lymphoma. Expert Rev Anticancer Ther 2007;7:257-273 (Pubitemid 46499210)
4. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-373
5. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-3861 (Pubitemid 36857857)
6. Robak E, Robak T. Monoclonal antibodies in the treatment of systemic Lupus erythematosus. Curr Drug Targets 2009;10:26-37.
7. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven M et al. Clin Immunol 2007;122:62-74.
8. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-1052
9. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005;153:620-625 (Pubitemid 41248223)
10. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001;137:269-272 (Pubitemid 32240777)
11. Schmidt E, Hunzelmann N, Broker, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006;31:503-8.
12. Schmidt E, Brockerm E, Goebeler M. Rituximab in treatment resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008:34:54-64.
13. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-1779 (Pubitemid 44631360)
14. Gürcan HM, Keskin DB, Stern JNH, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
15. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-1262
16. Chung I, Genovese MC, Fiorentino DF. A pilot study of rituximab in the treatment of patient with dermatomyositis. Arch Dermatol 2007;143;763-767 (Pubitemid 46955736)
17. Levine TD. Rituximab in the treatment of dermatomyositis: an open label pilot study. Arthritis Reum 2005;52:601-607 (Pubitemid 40216325)
18. Virgolini M, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004:58:299-309.
19. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N. A case of Rituximab-induced interstitial pneumonitis observed in systemic lupus erythematous. Letter to the editors. Rheumatology 2009 [in press].
20. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases:mixed responses and adverse effects. British J Dermatol 2007;156:352-356 (Pubitemid 46095965)
21. [No authors listed]. Rituxan warning. FDA Consum 2007;41:3.